Building a patient-focused therapeutic portfolio
Elixion’s initial focus spans oncology and autoimmune disorders with high unmet patient need and higher likelihood of clinical success. Programmes advance from in silico modelling to preclinical validation through our unique R&D approach.
Oncology candidates
Target validated, lead optimisation ongoing
- TNBC – In silico validation completed
- HER2-negative – In silico validation completed
Autoimmune disorder candidates
Early-stage biomarker/target co-localisation
«We are redefining what is possible in drug discovery by accelerating the path from concept to cure. Our mission is to create life-changing therapies. Quantum physics, combined with multi-omics and native AI, empowers us to do that at a scale never seen before.»
